We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01479413
First Posted: November 24, 2011
Last Update Posted: September 11, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Tiao-Lai Huang, Chang Gung Memorial Hospital
  Purpose

The investigators will investigate

  1. the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome.
  2. the relationships between aberrant mitochondria genes (single nucleotide polymorphism of D-loop region-related genes and haplogroup N9a), DISC1 gene polymorphism, and clinical phenotypes in Taiwanese populations.
  3. whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.

Condition
Schizophrenia

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs

Resource links provided by NLM:


Further study details as provided by Tiao-Lai Huang, Chang Gung Memorial Hospital:

Primary Outcome Measures:
  • Serum oxidative stress [ Time Frame: 15 months ]
    serum malondialdehyde (MDA) content, serum free thiols, serum glutathione, catalase, Superoxide dismutase, glutathione peroxidase, proapoptotic markers (bad and bax) and antiapoptotic markers (bcl-2 and bcl-x1), quantification of mitochondrial DNA

  • DISC1 gene polymorphism [ Time Frame: 15 months ]

Secondary Outcome Measures:
  • PANSS score [ Time Frame: 15 months ]
    Positive and Negative Syndrome Scale to reflect the severity of psychopathology

  • Obesity [ Time Frame: 15 months ]
    obesity defined by body mass index (BMI)>=26.4

  • Metabolic syndrome [ Time Frame: 15 months ]
  • Drug response [ Time Frame: 15 months ]

Biospecimen Retention:   Samples With DNA
Blood

Enrollment: 77
Study Start Date: August 2009
Study Completion Date: September 2013
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Schizophrenia

Detailed Description:

In past study, we had shown that there were significant differences in serum Lpo (lipid peroxidation) and Thiol levels between patients with schizophrenia and healthy controls. For patients taking risperidone, there were significant decreases in serum Thiol levels. In addition, there were also significant differences in age of onset of PPAR gamma coactivator 1α (PGC-1α) polymorphism for schizophrenia patients. Therefore, we want to know the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome.

In past study, we also found that there were significant differences in 10 SNPs located in the D-loop region-related genes between patients and healthy controls. Three SNPs could be found in Mitomap data, but another seven SNPs not been found in the Mitomap and they could be more confirmed. In addition, Tanaka et al. found that haplogroup N9a was related to diabetes and metabolic syndrome in Asia. Therefore, we were interested to clarify the relationships between above related mitochondria genes and clinical phenotypes in Taiwanese populations,.

In addition, we also want to see whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
This study will be conducted in our clinical setting. By a semi-structured interview for DSM-IV criteria, about 300 schizophrenic patients will be recruited in this study.
Criteria

Inclusion Criteria:

  1. Schizophrenic patients will be recruited in psychiatric inpatients and outpatients departments according to DSM-IV criteria by a semi-structured interview. The assessment will be done by two senior psychiatrists. The intra- rater and inter-rater reliability will be done before this project started.
  2. The patients had the ability to complete the written inform consent.

Exclusion Criteria:

  1. Alcohol abuse or dependence
  2. Smoking more than 1 pack per day
  3. Concurrent use of mood stabilizer or beta-blocker
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479413


Locations
Taiwan
Department of Psychiatry, Chang Gung Memorial Hospital
Kaohsiung, Taiwan
Sponsors and Collaborators
Chang Gung Memorial Hospital
Investigators
Principal Investigator: Tiao-Lai Huang, M.D. Chang-Gung Memorial Hospital, Kaohsiung
  More Information

Responsible Party: Tiao-Lai Huang, Head of Department of Psychiatry, Chang Gung Memorial Hospital
ClinicalTrials.gov Identifier: NCT01479413     History of Changes
Other Study ID Numbers: CMRPG891561
First Submitted: July 10, 2011
First Posted: November 24, 2011
Last Update Posted: September 11, 2013
Last Verified: September 2013

Keywords provided by Tiao-Lai Huang, Chang Gung Memorial Hospital:
Schizophrenia
Oxidative stress
Mitochondria

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs